BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $65.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM, generating $362.4 million in U.S. net product revenues in 2025, plus $105M in Beyonttra license/services revenue from Europe and Japan. Multiple Phase 3 programs... Read more
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $65.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — BridgeBio Pharma, Inc.
Latest news
- BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha — Seeking Alpha positive
- Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next - simply — simplywall.st negative
- Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail — The Globe and Mail positive
- BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus — GuruFocus positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAttruby and Beyonttra10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $65.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $61.72. Score 5.1/10, moderate confidence.
Take-profit target: $91.70 (+38.9% upside). Prior stop was $61.72. Stop-loss: $61.72.
Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Consecutive earnings misses (3).
BridgeBio Pharma, Inc. trades at a P/E of N/A (forward 174.2). TrendMatrix value score: 3.0/10. Verdict: Sell.
30 analysts cover BBIO with a consensus score of 4.3/5. Average price target: $102.
What does BridgeBio Pharma, Inc. do?BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM,...
BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM, generating $362.4 million in U.S. net product revenues in 2025, plus $105M in Beyonttra license/services revenue from Europe and Japan. Multiple Phase 3 programs target 2026 BLA submissions including navenibart (HAE), infigratinib (achondroplasia), and encaleret (ADH1). The business is substantially dependent on Attruby and Beyonttra for near-term revenues.